Member Info for MisterPositive

Also very much like detailed analysis by Mr Porsch1 the other day about Genedrive tests could very much be extended to Cardiovascular space also. That would be awesome.

Will be allocating a large chunk of my new ISA allowance here also especially at these prices.

With a potential £200m Buy Out price next year.

UK annual revenues target alone £8.5m potential from AIHL is higher than current £7m MCap. Then add revenues from Europe and rest of the World.

Stroke test revenues will be lot more than this.

Funding overhang stopped the re-rate from last week STROKE tests RNS but probably already arranged and forward sold in my opinion. Just need confirmation. When buying pressure kicks in this moves higher in Half penny increments at lightning speed.

Traders at it again looking for lower entry !!!

Well this is low already....

I think this System fella has lost the plot 🤔

Been nibbling here anything below 6p i think is a fantastic price after last weeks RNS.

Had it not been for the funding overhang we would be over +10p already.

As a general rule of thumb for Annual revenues of circa £10m (to start with)...MCap has to be £100m

Using multipler of 10 as a rough guide.

Justice2u

With you on this one. Rise was held back last week after a superb RNS re STROKE tests mainly due to funding overhang. Once that is out of the way, this is going to rocket higher for a proper rise that has been overdue.

Funding might have been agreed with the broker lets say around 6p (my guess) even though i would have preferred higher. Either way this is going to rocket higher when its done.

Lot of good news still to come. Might be good to get it out of the way for a proper strong rise with NO funding overhang.

Public cnsultation on STROKE tests started in May 2023 and final Consultation period ends on 26 Apr 2024.

NICE publication date of full recommendation is 10 July 2024. I would expect Full recommendation News announcement soon after 26 Apr 2024 with July detailed publication report just a formality.

I would expect a gradual rise between now and 26 April 2024 which is only 3 weeks time as folks start taking positions.

There is already lot of data available for STROKE tests hence will be fast tracked. AIHL was something new and unique to Genedrive being first to market and no competition in this area.

We are on the cusp of revenue generation with potential annual revenues of circa £100m.

Not interested in 2-3p gains here and there. I am looking for much higher and substantial gains in the 60p - 80p bracket. Happy to wait.

I expect a substantial re-rate in price around end of April / start of May towards 20p first target. We got £1.5m cash in bank. They can raise around 15p from investors and end the RF deal for good. That will also allow RF to exercise their 10p warrants which would bring in even more CASH in our bank. By end of Summer we should already be earning revenue from sales.

I repeat 2024 is shaping up to be pivotal year with hugely attractive ROI from 6p upwards. GLA

Taking company private was a dumb / stupid and irrelevant question whichever mor0n asked it. No wonder the reaction.

Whole purpose of listing is to raise funds from the market for growth & expansion of the business as and when required.

Some folks do not understand the basics. Traders jumped on that in the heat of the moment creating unnecessary volatilty for their own gain.

I expect Genedrive to also list in USA at some point in the future. US investors have far bigger appetite for bio-tech stocks like Genedrive especially with POC pharmacogenetics being the future.

Good thing is company does not want to use RF deal anymore and looking to replace it with good old standard placing with retail investors down the road probably at a higher price giving also RF a chance to exercise their 10p warrants etc.

Further updates/RNS in coming days/ weeks should be more revealing.

I thought presentation overall was fine.

There will more news.

Some folks who sold higher talking it down.

Roger the dodger...though you were already out.

Genedrive has ZERO debt.

If they get a lowball cheap Buy Out offer of £50m or £100m

Sale proceeds go to SHAREHOLDERS coz there are NO DEBT HOLDERS.

Public or Private is red herring and Offtopic.

RF is on the way out.

If they exercise their warrants that would be upwards of +10p.

Expecting positive updates next week pushing price upwards towards +15p before RF exercise their warrants when they are in the money.

Funds can be raised easily from Riverfort exercising their warrants.

Lowest warrants Exercise price @ 10.86p if i am not mistaken.

Plus we got £1.5m cash currently. No need for significant funds to be raised immediately as some keep spouting for their own agenda.

With STROKE tests RNS earlier this week, Genedrive would become even more attractive to any US partner coming in with 2 leading products under their wings.

Valuation equation has changed a lot in GDR favour now compared to few months ago.

Yes. He has an impressive track record.

2024 looking to be pivotal year for Genedrive after many years of product development. Genedrive finally on the cusp of some juicy ROI for holders.

The Company will provide a live presentation to accompany the results, presented by Chief Executive Officer James Cheek, Chief Financial Officer Russ Shaw and Chief Scientific Officer Gino Miele, on Friday, 5 April 2024 at 10.00am.

 The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor 

That is 52% of the entire issued Share Capital.

18 x daily average of 2m shares....wow

Wadogara.

Strong momentum brings superb gains as we have seen in the past here at Genedrive.

Speculation yes but that is what we all do. With 2 great products backed now by NICE recommendations, starting to get markets attention and pharma industry players.

Taken Genedrive years to get to this point with 2024 shaping up to be pivotal year for holders.

With only 150m odd shares about, moves here can be fast n furious. I can handle the volatility with eye on the prize and end game here which could also lead to early BuyOut offer for the company. Speculation yes - otherwise we will not be here.

Word Funding is not "Taboo". Even big Multi-national cos raise funds for expansion & growth.

Few scenarios below:

1) Incoming US pharma partner invests upfront cash for future sales royalties from US sales.

2) Incoming partner invests a large sum for % Equity stake in Genedrive.

3) Genedrive raise e.g. £4m around 12p when price is mid Double digits and removing any uncertainty with a clear run to 40p - 50p and higher.

Agree 100%. If RF were not busy selling their last tranche of shares yesterday we would have hit 10p yesterday.

Expect this to go lot higher on strong momentum in coming weeks. Biggest price gains come from strong momentum and higher volumes which traders love. Current MCap is ridiculously low.

This was around 43p last year before RF deal.

RF now on the way out and both AIHL and STROKE tests gaining traction with NICE recommendations, this can easily get back to 43p and beyond that in 2024.